Every 10-Q that Viatris Inc. (VTRS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VTRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTRS filings page.
Viatris reported Q2 2026 total revenues of $3,756.8 million, up from $3,582.1 million a year earlier, driven by strong brands such as Lipitor ($914.2 million), Norvasc, and other established products. Net sales for the first half of 2026 were $7,255.6 million versus $6,812.2 million in 2025.
The company posted a Q2 2026 net loss of $118.8 million (basic and diluted EPS $(0.10)), but for the first six months generated net earnings of $57.6 million, compared with a net loss of $3,046.6 million in the prior-year period, which had included a $2,936.8 million goodwill impairment. First-half operating cash flow was $770.1 million.
At June 30, 2026, Viatris held $886.5 million in cash and cash equivalents and long-term debt of $11,612.4 million, reflecting repayment of $1.675 billion 2026 Senior Notes and issuance of €650.0 million 4.250% Senior Notes due 2033 plus a new ¥40 billion term loan facility. The company continued returning capital via dividends of $0.12 per share each quarter and repurchased about 9.4 million shares for $150.0 million in the first half, bringing cumulative repurchases under its program to approximately 103.5 million shares for $1.15 billion as of June 30, 2026.
Viatris Inc. reported a return to profitability for the quarter ended March 31, 2026. Total revenues rose to $3.52 billion from $3.25 billion a year earlier, driven by higher net sales across Developed Markets and Greater China. Net earnings reached $176.4 million, compared with a prior-year net loss of $3.04 billion that was heavily affected by goodwill impairment.
Basic and diluted earnings per share were $0.15 versus a loss of $2.55 per share in the prior-year period. Operating cash flow was $388.3 million, and cash and cash equivalents increased to $1.80 billion while long-term debt remained around $12.4 billion. The company maintained a quarterly dividend of $0.12 per share.
Viatris launched a major restructuring program following its enterprise-wide strategic review, targeting a workforce reduction of up to 10% and expecting total pre-tax charges of $700–$850 million over roughly three years; it recorded $77.9 million of related charges this quarter. A fire at its Nashik, India facility led to $71.9 million in charges and a temporary production halt, with full operations expected to resume in July 2026. The company also closed the sale of its Biocon Biologics convertible preferred stake for $400 million in cash plus $415 million in Biocon equity shares.
Viatris Inc. (VTRS) reported Q3 2025 results with total revenues of $3,759.9 million (essentially flat year over year) and a net loss of $128.2 million versus net earnings of $94.8 million a year ago. Net sales were $3,747.5 million. Gross profit was $1,371.5 million, down from $1,459.2 million as cost of sales rose. Operating income was $178.8 million, tempered by higher other expense.
Year-to-date, results reflect significant non-cash charges: a goodwill impairment of $2,936.8 million contributed to a YTD net loss of $3,174.8 million on revenues of $10,596.3 million. Operating cash flow was solid at $1,500.1 million. Cash and equivalents were $975.3 million; long‑term debt was $12,487.6 million with the current portion at $1,951.9 million. The company continued returning capital via share repurchases ($415.4 million YTD) and dividends ($423.0 million YTD). Selected products grew, including Lipitor $396.1 million and EpiPen $157.2 million in Q3. Shares outstanding were 1,151,769,872 as of November 3, 2025.